Meta-analysis Of The Efficacy And Aes Of Rifaximin In Patients With The Irritable Bowel Syndrome

ObjectiveTo evaluate the efficacy and AEs of rifaximin in patients with IBS.MethodsRandomized controlled trials of rifaximin in patients with the Irritable Bowel Syndrome were searched in Pub Med、Web of Science、Google scholor、Medline and Cochrane Library、China Academic Literature Full-text Database、Chinese VIP Full-text Database 、 Wanfang medical Full-text Database between January 1,1950 and May29,2014. We evaluate the primary endpoint is global IBS symptom improvement(GLSI)after treatment and secondary endpoints are bloating improvement and adverse events(AEs) during the treatment and follow-up.ResultsRifaximin could obviously improve the symptoms of IBS of patients than in the placebo group(OR=1.55, 95%CI[1.32,1.84],I2 =17%);The phenomenon of IBS related bloating relative significantly(OR=1.56,95%CI[1.32,1.85],I2=0%);Thort-term rates of adverse events was lower(OR=0.81,95%CI[0.66,0.99],I2=0%).ConclusionRifaximin can improve the globle symptoms and bloating of IBS significantly and have a lower rate of adverse reaction, It is effective and safety in the treatment of IBS.